ESCMID weekly news 13.09.2022


Having trouble viewing this email? View in your browser.


 

Weekly News
13 September 2022



Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


 

IMMEM XIII starts tomorrow 14 September 2022

The 13th International Meeting on Microbial Epidemiological Markers starts tomorrow in Bath, UK, 14-17 September 2022. This year focus is on epidemiological surveillance through whole genome sequencing. You can find the final programme here and make sure to follow @ESGEM_ESCMID who will be live tweeting the event!

 


 


ESCMID survey on textbook used in CM/ID/IC

Please help us by answering this short survey, aimed at understanding how ESCMID members learn most effectively. Have your say in the development of ESCMID learning/continuous professional development resources.

Register for this online education course by 2 October!

This course aims to update the audience on the collateral healthcare damages caused by the COVID-19 pandemic, concerning prevention and management of infectious diseases, clinical microbiology, IPC and ASPs in LMICs, and to assess strategies for normal activities resumption.


ESCMID eAcademy course with EUCAST

The course consists of seven online self-paced modules with recorded talks and assignments. A live seminar will be scheduled for each module, for experts to answer your questions. The first module will launch on 7 November 2022. Join the mailing list here to be notified when registration opens.

Call for funded observerships opens today!

The new call for 50 funded observerships opens today. Don't miss this prestigious opportunity to perform cutting edge clinical and scientific activities in renowned centres and make new friends and colleagues. Find the ECC that suits you and get your endorsement letter!


Register now for ESCMID/Ecraid Postgraduate Course

The purpose of the workshop is to provide the participants with tools on how to phrase a research question; choose the appropriate design and methods to address it; avoid biases; and write an optimal report. Find out more about the programme here.

Delta and Omicron variants carrying resistance-associated mutations

This study highlights the importance of monitoring for early in vivo selection of mutations associated with reduced susceptibility of mAb therapies and how virological surveillance of genetically resistant viruses to available therapies is a priority for patients and the community.



 




 

 

 

Nahoru